Natus Medical Inc (NASDAQ:BABY) has received an average rating of “Hold” from the seven ratings firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $49.00.

Several brokerages have issued reports on BABY. Zacks Investment Research cut Natus Medical from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 11th. Benchmark reissued a “buy” rating and issued a $49.00 target price (down from $55.00) on shares of Natus Medical in a research report on Tuesday. William Blair cut Natus Medical from an “outperform” rating to a “market perform” rating in a research report on Monday, January 8th. Finally, BidaskClub cut Natus Medical from a “sell” rating to a “strong sell” rating in a research report on Saturday, January 6th.

Shares of Natus Medical (NASDAQ BABY) traded down $0.30 during trading hours on Friday, reaching $28.25. The company’s stock had a trading volume of 362,985 shares, compared to its average volume of 605,065. The stock has a market capitalization of $880.10, a PE ratio of -470.83 and a beta of 0.84. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.21 and a quick ratio of 3.36. Natus Medical has a fifty-two week low of $28.05 and a fifty-two week high of $43.60.

Natus Medical (NASDAQ:BABY) last announced its earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.02. The business had revenue of $122.60 million for the quarter, compared to analysts’ expectations of $122.41 million. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The business’s revenue for the quarter was up 34.9% on a year-over-year basis. During the same period last year, the firm posted $0.39 earnings per share. equities analysts forecast that Natus Medical will post 1.64 earnings per share for the current year.

In other news, Director William M. Moore sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $41.01, for a total value of $205,050.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Dong Chune Christopher Chung sold 12,642 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $42.91, for a total value of $542,468.22. Following the completion of the transaction, the vice president now directly owns 141,414 shares in the company, valued at approximately $6,068,074.74. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of BABY. Benjamin F. Edwards & Company Inc. raised its stake in Natus Medical by 2,085.6% during the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 2,732 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 2,607 shares during the period. Riverhead Capital Management LLC raised its stake in Natus Medical by 90.9% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock valued at $107,000 after purchasing an additional 1,364 shares during the period. SG Americas Securities LLC bought a new stake in Natus Medical during the 3rd quarter valued at approximately $138,000. Victory Capital Management Inc. raised its stake in Natus Medical by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 3,744 shares of the medical equipment provider’s stock valued at $140,000 after purchasing an additional 560 shares during the period. Finally, Flinton Capital Management LLC raised its stake in Natus Medical by 82.0% during the 2nd quarter. Flinton Capital Management LLC now owns 3,774 shares of the medical equipment provider’s stock valued at $141,000 after purchasing an additional 1,700 shares during the period. 99.87% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/19/natus-medical-inc-baby-given-consensus-rating-of-hold-by-analysts.html.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.